Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?

Eli Lilly's biggest growth drivers today are its weight loss drugs.Eli Lilly (LLY -0.14%) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight loss: Mounjaro and Zepbound. They're both based on the same molecule, but regulators approved the product for type 2 diabetes under the name Mounjaro and specifically for weight management under the name Zepbound.The company won approval for Mounj ...